EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Generalized myasthenia gravis with acetylcholine receptor antibodies: A guidance for treatment

Nils Erik Gilhus iD, Henning Andersen iD, Linda Kahr Andersen iD, Marion Boldingh iD, Sini Laakso iD, Margret Oddny Leopoldsdottir, Sidsel Madsen, Fredrik Piehl iD, Trine Haug Popperud iD, Anna Rostedt Punga iD, Liselotte Schirakow, John Vissing iD

European Journal of Neurology · 2024-05 · 31 (5)

DOI: 10.1111/ene.16229 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Neurology, online erschienen am 06.02.2024. Verfasst von Nils Erik Gilhus und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Haukeland University Hospital, Bergen, Norway. Hauptthemen laut MEDLINE: Myasthenia Gravis, Receptors, Cholinergic. Die Arbeit wurde bisher 95-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Danish Muscular Dystrophy Organization.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Generalized myasthenia gravis (MG) with antibodies against the acetylcholine receptor is a chronic disease causing muscle weakness. Access to novel treatments warrants authoritative treatment recommendations. The Nordic countries have similar, comprehensive health systems, mandatory health registers, and extensive MG research.

Methods

MG experts and patient representatives from the five Nordic countries formed a working group to prepare treatment guidance for MG based on a systematic literature search and consensus meetings.

Results

Pyridostigmine represents the first‐line symptomatic treatment, while ambenonium and beta adrenergic agonists are second‐line options. Early thymectomy should be undertaken if a thymoma, and in non‐thymoma patients up to the age of 50–65 years if not obtaining remission on symptomatic treatment. Most patients need immunosuppressive drug treatment. Combining corticosteroids at the lowest possible dose with azathioprine is recommended, rituximab being an alternative first‐line option. Mycophenolate, methotrexate, and tacrolimus represent second‐line immunosuppression. Plasma exchange and intravenous immunoglobulin are used for myasthenic crises and acute exacerbations. Novel complement inhibitors and FcRn blockers are effective and fast‐acting treatments with promising safety profiles. Their use depends on local availability, refunding policies, and cost–benefit analyses. Adapted physical training is recommended. Planning of pregnancies with optimal treatment, information, and awareness of neonatal MG is necessary. Social support and adaptation of work and daily life activities are recommended.

Conclusions

Successful treatment of MG rests on timely combination of different interventions. Due to spontaneous disease fluctuations, comorbidities, and changes in life conditions, regular long‐term specialized follow‐up is needed. Most patients do reasonably well but there is room for further improvement. Novel treatments are promising, though subject to restricted access due to costs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myasthenia GravisReceptors, CholinergicHumansAutoantibodiesImmunosuppressive AgentsPractice Guidelines as Topic

Stichwörter der Autor:innen

acetylcholine receptor antibodiesimmunosuppressionmyasthenia gravisthymustreatment

Substanzen

Receptors, CholinergicAutoantibodiesImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Neurology, Haukeland University Hospital, Bergen, Norway.
  • Department of Clinical Medicine, University of Bergen, Bergen, Norway.
  • Department of Neurology, Aarhus University Hospital, Aarhus, Denmark.
  • Copenhagen Neuromuscular Center, Department of Neurology, Copenhagen University Hospital, Copenhagen, Denmark.
  • Department of Neurology, Oslo University Hospital, Oslo, Norway.
  • Department of Neurology, Brain Center, Helsinki University Hospital, Helsinki, Finland.

ORCID-Profile: Nils Erik Gilhus, Henning Andersen, Linda Kahr Andersen, Marion Boldingh, Sini Laakso, Fredrik Piehl, Trine Haug Popperud, Anna Rostedt Punga, John Vissing

Förderung

  • Danish Muscular Dystrophy Organization

Zitieren

APA

Gilhus, N. E., Andersen, H., Andersen, L. K., Boldingh, M., Laakso, S., Leopoldsdottir, M. O., Madsen, S., Piehl, F., Popperud, T. H., Punga, A. R., Schirakow, L., & Vissing, J. (2024). Generalized myasthenia gravis with acetylcholine receptor antibodies: A guidance for treatment. European Journal of Neurology, 31(5). https://doi.org/10.1111/ene.16229

Vancouver

Gilhus NE, Andersen H, Andersen LK, Boldingh M, Laakso S, Leopoldsdottir MO, et al. Generalized myasthenia gravis with acetylcholine receptor antibodies: A guidance for treatment. European Journal of Neurology. 2024;31(5). doi:10.1111/ene.16229

BibTeX
@article{Gilhus2024,
  author = {Gilhus, Nils Erik and Andersen, Henning and Andersen, Linda Kahr and Boldingh, Marion and Laakso, Sini and Leopoldsdottir, Margret Oddny and Madsen, Sidsel and Piehl, Fredrik and Popperud, Trine Haug and Punga, Anna Rostedt and Schirakow, Liselotte and Vissing, John},
  title = {Generalized myasthenia gravis with acetylcholine receptor antibodies: A guidance for treatment},
  journal = {European Journal of Neurology},
  year = {2024},
  volume = {31},
  number = {5},
  doi = {10.1111/ene.16229}
}
Kostenlos starten →